Liprolog Basal: Uses, Dosage & Side Effects
An intermediate-acting insulin analogue for basal blood glucose control in patients with type 1 and type 2 diabetes mellitus
Liprolog Basal (insulin lispro protamine) is a prescription intermediate-acting insulin analogue used for the management of blood glucose levels in patients with type 1 and type 2 diabetes mellitus. It provides sustained basal insulin coverage by combining the modified insulin lispro molecule with protamine, which delays absorption from the subcutaneous injection site and extends the duration of action to approximately 15–24 hours. Liprolog Basal is supplied as a suspension for injection in 3 mL cartridges at a concentration of 100 IU/mL, designed for use with compatible insulin pen devices. It is typically administered once or twice daily and is commonly used alongside a rapid-acting insulin (such as regular Liprolog) at mealtimes as part of a basal-bolus insulin regimen, offering flexible and physiological glucose control.
Quick Facts: Liprolog Basal
Key Takeaways
- Liprolog Basal (insulin lispro protamine) is an intermediate-acting insulin analogue that provides sustained basal insulin coverage for approximately 15–24 hours, helping maintain blood glucose levels between meals and overnight.
- It is indicated for both type 1 and type 2 diabetes mellitus and is typically used as part of a basal-bolus regimen in combination with a rapid-acting insulin at mealtimes.
- The cartridge must be gently rolled or inverted (never shaken) before each injection to ensure uniform suspension, and injection sites should be rotated within the same body region to prevent lipodystrophy.
- Hypoglycemia is the most common and potentially serious side effect; patients must be educated to recognize symptoms including sweating, trembling, dizziness, and confusion, and should always carry a source of fast-acting glucose.
- Unopened cartridges should be stored refrigerated (2–8°C); once in use, the cartridge may be kept at room temperature (below 30°C) for up to 28 days, after which it must be discarded.
What Is Liprolog Basal and What Is It Used For?
Liprolog Basal contains insulin lispro protamine as its active ingredient, which is a modified form of human insulin produced using recombinant DNA technology in Escherichia coli. Insulin lispro itself is a rapid-acting insulin analogue that differs from human insulin by the reversal of the amino acids proline and lysine at positions B28 and B29 of the insulin B-chain. In Liprolog Basal, this modified insulin is combined with protamine sulfate to form a crystalline suspension. The protamine complexation slows the rate of absorption from the subcutaneous injection site, converting what would otherwise be a rapid-acting insulin into an intermediate-acting preparation with a prolonged duration of effect.
The pharmacokinetic profile of Liprolog Basal reflects its modified absorption characteristics. After subcutaneous injection, the onset of action typically occurs within 1 to 2 hours. The insulin effect then gradually increases, reaching a peak activity between 4 and 12 hours post-injection. The overall duration of action extends to approximately 15 to 24 hours, depending on the dose, injection site, blood flow, temperature, and level of physical activity. This pharmacokinetic profile is broadly comparable to that of NPH (Neutral Protamine Hagedorn) insulin, also known as isophane insulin, which has been a cornerstone of basal insulin therapy for decades.
The primary physiological role of any insulin preparation is to mimic the action of endogenous insulin produced by the beta cells of the pancreas. In healthy individuals, the pancreas continuously secretes a small baseline amount of insulin throughout the day and night (basal secretion), which regulates fasting blood glucose levels by suppressing hepatic glucose production and promoting glucose uptake in peripheral tissues. Additionally, larger boluses of insulin are released in response to meals to handle the postprandial rise in blood glucose. In patients with diabetes, this natural insulin secretory pattern is impaired or absent, necessitating exogenous insulin replacement.
Liprolog Basal is specifically designed to replicate the basal component of insulin secretion. By providing a steady, extended release of insulin activity over many hours, it helps control fasting blood glucose levels and prevents excessive glucose production by the liver between meals and overnight. This is particularly important because uncontrolled hepatic glucose output is a major contributor to fasting hyperglycemia in diabetes. When used as part of a basal-bolus regimen — where Liprolog Basal provides background coverage and a rapid-acting insulin (such as regular Liprolog/insulin lispro) covers mealtime glucose excursions — patients can achieve more physiological and flexible glucose control.
Liprolog Basal is indicated for the treatment of adults, adolescents, and children with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. This includes patients with type 1 diabetes (where the pancreas produces little or no insulin) and type 2 diabetes (where insulin resistance and progressive beta-cell failure eventually necessitate insulin therapy). In type 1 diabetes, Liprolog Basal is always used alongside rapid-acting mealtime insulin. In type 2 diabetes, it may be used alone as add-on therapy to oral antidiabetic agents, or in combination with mealtime insulin depending on the stage of the disease and the degree of glycemic control required.
The basal-bolus approach attempts to mimic the natural insulin secretion pattern of a healthy pancreas. Liprolog Basal provides the continuous background (basal) insulin needed to control blood sugar between meals and overnight, while a separate rapid-acting insulin is injected before each meal to handle the glucose spike from food. This approach offers greater flexibility in meal timing and content compared with fixed-dose insulin regimens.
What Should You Know Before Taking Liprolog Basal?
Contraindications
The use of Liprolog Basal is contraindicated in certain situations where administration could pose significant risks to the patient. The primary contraindication is hypersensitivity to insulin lispro or to any of the excipients contained in the formulation. These excipients include protamine sulfate, metacresol (m-cresol), phenol, glycerol, dibasic sodium phosphate heptahydrate, zinc oxide, hydrochloric acid and sodium hydroxide (for pH adjustment), and water for injections. If you have a known allergy to any of these components, you must not use Liprolog Basal.
Liprolog Basal must never be administered during episodes of hypoglycemia (low blood sugar). Injecting insulin when blood glucose levels are already below normal can lead to severe hypoglycemia, which is a medical emergency that can cause loss of consciousness, seizures, and in extreme cases, brain damage or death. Always check your blood glucose level before administering Liprolog Basal if you are unsure whether you are experiencing hypoglycemia.
Additionally, Liprolog Basal must never be administered intravenously. As a protamine-crystalline suspension, it is designed exclusively for subcutaneous injection. Intravenous administration of an insulin suspension can cause severe, unpredictable hypoglycemia and other adverse effects. Liprolog Basal should also not be used in insulin infusion pumps, as only clear, rapid-acting insulin solutions are suitable for continuous subcutaneous insulin infusion (CSII) systems.
Warnings and Precautions
Hypoglycemia is the most common serious adverse reaction associated with insulin therapy, including Liprolog Basal. Severe hypoglycemia can lead to unconsciousness, seizures, and death. Always carry a source of fast-acting glucose (glucose tablets, juice, or sugar) and ensure that family members, caregivers, and colleagues know how to recognize and treat hypoglycemia. If you experience severe hypoglycemia requiring assistance, seek medical attention immediately.
Before starting Liprolog Basal, discuss the following conditions and situations with your healthcare provider, as they may necessitate dose adjustments or closer monitoring:
- Renal impairment: Patients with kidney disease may have reduced insulin clearance, leading to a prolonged duration of insulin action and an increased risk of hypoglycemia. Regular monitoring of blood glucose and potential dose reduction may be necessary. The degree of dose adjustment depends on the severity of renal impairment.
- Hepatic impairment: Liver disease can reduce the capacity for gluconeogenesis (glucose production) and insulin metabolism, thereby increasing the risk of hypoglycemia. Patients with hepatic impairment may require reduced insulin doses and more frequent blood glucose monitoring.
- Adrenal, pituitary, or thyroid disorders: Deficiencies in counter-regulatory hormones (such as cortisol, growth hormone, or thyroid hormones) can increase susceptibility to hypoglycemia. Conversely, excess of these hormones (e.g., in hyperthyroidism or Cushing syndrome) can increase insulin requirements. Dose adjustments should be guided by blood glucose monitoring.
- Changes in physical activity: Increased exercise enhances insulin sensitivity and glucose uptake by muscles, which can lower blood glucose levels and necessitate a reduction in insulin dose or increased carbohydrate intake. Conversely, reduced physical activity may require dose increases.
- Changes in diet: Alterations in meal composition, timing, or caloric content can affect blood glucose levels and may require corresponding insulin dose adjustments. Work with your healthcare team or diabetes educator to understand how food affects your insulin needs.
- Illness and stress: Intercurrent illness (infection, fever, trauma, surgery) and emotional stress typically increase insulin requirements due to the release of counter-regulatory stress hormones. More frequent blood glucose monitoring is essential during these periods.
- Concomitant medications: Many medications can affect blood glucose levels. Inform your doctor about all prescription and non-prescription medications, vitamins, and supplements you are taking.
Pregnancy and Breastfeeding
Maintaining good glycemic control is essential during pregnancy to reduce the risk of complications for both the mother and the baby. Poorly controlled diabetes during pregnancy is associated with an increased risk of congenital malformations, macrosomia (excessively large baby), neonatal hypoglycemia, pre-eclampsia, and other adverse outcomes. Women with pre-existing diabetes who are planning pregnancy or who become pregnant should work closely with their diabetes care team to optimize blood glucose control before conception and throughout pregnancy.
Insulin requirements typically change during pregnancy. During the first trimester, insulin requirements may decrease, potentially increasing the risk of hypoglycemia. During the second and third trimesters, insulin resistance progressively increases (driven by placental hormones such as human placental lactogen, progesterone, and cortisol), often requiring significant increases in insulin doses. After delivery, insulin requirements usually drop rapidly and return toward pre-pregnancy levels. Close monitoring and frequent dose adjustments are necessary throughout pregnancy and the postpartum period.
Insulin lispro protamine does not cross the placenta in significant amounts, making it an appropriate choice for insulin therapy during pregnancy. However, the overall insulin regimen should be individualized and managed by a specialist. The European Medicines Agency (EMA) and major diabetes guidelines consider insulin lispro to be an acceptable insulin analogue for use during pregnancy based on extensive clinical experience and safety data.
Patients who are breastfeeding may also require adjustments to their insulin doses and dietary intake. Insulin is not absorbed from the gastrointestinal tract and is therefore not expected to affect the breastfed infant. Breastfeeding mothers with diabetes can safely use Liprolog Basal, but should be aware that lactation may reduce insulin requirements due to the energy expenditure associated with milk production.
Children and Adolescents
Liprolog Basal can be used in children and adolescents with diabetes mellitus who require basal insulin therapy. The dosing principles are the same as for adults, but insulin requirements in children can be highly variable and are influenced by growth, puberty, activity levels, and dietary habits. During puberty, insulin resistance typically increases due to the effects of growth hormone, often requiring higher insulin doses. Regular monitoring by a pediatric endocrinologist or diabetes specialist is recommended. Parents and caregivers should be trained in insulin administration, blood glucose monitoring, and recognition and management of hypoglycemia.
Driving and Operating Machinery
Hypoglycemia can impair concentration, reaction time, and judgment, which may affect your ability to drive safely or operate machinery. Patients using Liprolog Basal should test their blood glucose levels before driving and at regular intervals during long journeys. Do not drive or operate hazardous machinery if your blood sugar is low or if you feel any symptoms of hypoglycemia such as dizziness, confusion, or blurred vision. Patients who have reduced awareness of hypoglycemia (hypoglycemia unawareness) should be advised about the particular risk this poses for driving safety.
How Does Liprolog Basal Interact with Other Drugs?
Unlike small-molecule drugs that undergo hepatic metabolism and can interact through cytochrome P450 enzyme inhibition or induction, insulin lispro protamine is a peptide hormone that is degraded through general proteolytic pathways. It does not interact with other drugs through pharmacokinetic mechanisms. However, numerous medications have pharmacodynamic interactions with insulin by independently affecting blood glucose levels, either enhancing or counteracting the glucose-lowering effect of insulin. These interactions are clinically significant and must be considered when prescribing or adjusting insulin therapy.
The table below summarizes the most important drug interactions with Liprolog Basal. Patients should always inform their healthcare provider about all medications they are taking, including over-the-counter drugs, herbal supplements, and vitamins, as these may affect blood glucose control and insulin dose requirements.
| Drug / Drug Class | Effect on Blood Glucose | Clinical Significance |
|---|---|---|
| Oral antidiabetic agents (metformin, sulfonylureas, SGLT2 inhibitors) | Lowers blood glucose | Increased hypoglycemia risk; may need insulin dose reduction |
| ACE inhibitors (enalapril, ramipril, lisinopril) | May lower blood glucose | Enhanced insulin sensitivity; monitor glucose closely |
| MAO inhibitors | May lower blood glucose | Increased hypoglycemia risk; close monitoring required |
| Beta-blockers (propranolol, atenolol, metoprolol) | May mask hypoglycemia symptoms | Tachycardia and tremor may be masked; sweating persists. Increased monitoring needed |
| Corticosteroids (prednisolone, dexamethasone) | Raises blood glucose | May require significant insulin dose increase |
| Thiazide diuretics (hydrochlorothiazide, indapamide) | Raises blood glucose | May reduce insulin effectiveness; dose adjustment may be needed |
| Thyroid hormones (levothyroxine) | Raises blood glucose | May increase insulin requirements |
| Sympathomimetics (salbutamol, terbutaline) | Raises blood glucose | Temporary increase in insulin requirements during use |
| Octreotide / Somatostatin analogues | Variable (may lower or raise) | Unpredictable effect; close glucose monitoring essential |
| Alcohol | May lower blood glucose (delayed) | Risk of delayed hypoglycemia; avoid excessive intake |
Major Interactions
The most clinically important interactions with Liprolog Basal involve medications that significantly lower blood glucose, as the combined hypoglycemic effect can lead to severe or prolonged hypoglycemia. The combination of insulin with sulfonylureas (such as glimepiride, glipizide, or glyburide) carries a particularly high risk, as both drug classes independently promote insulin-mediated glucose disposal. When adding or adjusting oral antidiabetic therapy in a patient already on Liprolog Basal, the insulin dose often needs to be reduced and blood glucose monitored more frequently during the transition period.
Corticosteroids represent one of the most impactful hyperglycemic interactions. Systemic corticosteroids (such as prednisolone, methylprednisolone, and dexamethasone) dramatically increase insulin resistance and hepatic glucose production, and patients starting corticosteroid therapy may require insulin dose increases of 20–50% or more. Conversely, when corticosteroids are tapered or discontinued, insulin doses must be reduced to prevent hypoglycemia. This interaction requires close communication between the patient and healthcare team.
Beta-blockers pose a unique risk because they can mask the adrenergic symptoms of hypoglycemia (such as rapid heartbeat and tremor), leaving the patient unaware that their blood sugar has dropped dangerously low. Non-selective beta-blockers (such as propranolol) are more problematic in this regard than cardioselective agents (such as bisoprolol or metoprolol). Patients taking beta-blockers should be counseled about alternative hypoglycemia warning signs, such as sweating (which is not masked by beta-blockers), and should monitor their blood glucose more frequently.
Minor Interactions
Several other drug classes have more modest effects on blood glucose that are generally manageable with routine monitoring. Fibrates and salicylates (including high-dose aspirin) may have mild glucose-lowering effects. Oral contraceptives and hormone replacement therapy may modestly increase insulin requirements. Niacin (vitamin B3) at high doses can impair glucose tolerance. Diazoxide, used to treat hypoglycemia in other contexts, has a hyperglycemic effect that can reduce insulin effectiveness. In all cases, awareness of these interactions and proactive blood glucose monitoring allow timely dose adjustments.
Alcohol inhibits hepatic gluconeogenesis, which can cause delayed hypoglycemia several hours after drinking, particularly when combined with insulin therapy. This risk is greatest with consumption on an empty stomach or after exercise. Patients using Liprolog Basal should avoid excessive alcohol consumption and should never drink alcohol without also eating carbohydrate-containing food. Blood glucose should be monitored before bed after evening alcohol consumption.
What Is the Correct Dosage of Liprolog Basal?
There is no universal dose of Liprolog Basal that applies to all patients. Insulin dosing is one of the most individualized aspects of diabetes therapy, and the appropriate dose depends on numerous factors including the type of diabetes, body weight, level of physical activity, dietary habits, other medications, overall health status, and the presence of insulin resistance. Your healthcare provider will determine the initial dose and adjust it based on your blood glucose monitoring results and HbA1c (glycated hemoglobin) levels.
In general, the total daily insulin requirement for a patient with type 1 diabetes ranges from 0.4 to 1.0 IU per kilogram of body weight per day, with approximately 40–60% of this total allocated to basal insulin and the remainder distributed across mealtime (bolus) doses. For patients with type 2 diabetes who are initiating basal insulin, a common starting dose is 0.1–0.2 IU/kg/day (or 10 IU), which is then titrated upward by 1–2 IU every 2–3 days based on fasting blood glucose targets.
| Patient Group | Typical Starting Dose | Administration | Notes |
|---|---|---|---|
| Adults — Type 1 Diabetes | 40–60% of total daily insulin dose | Once or twice daily | Always used with rapid-acting mealtime insulin |
| Adults — Type 2 Diabetes | 0.1–0.2 IU/kg/day (or 10 IU) | Usually once daily at bedtime | Titrate by 1–2 IU every 2–3 days to fasting glucose target |
| Children and Adolescents | Individualized based on weight and needs | Once or twice daily | Requirements increase during puberty; specialist supervision essential |
| Elderly (≥65 years) | Conservative initial dosing | Once or twice daily | Higher hypoglycemia risk; less stringent glucose targets may be appropriate |
| Renal Impairment | Reduced dose may be required | Per physician guidance | Decreased insulin clearance; increased hypoglycemia risk |
Adults
In adults with type 1 diabetes, Liprolog Basal is used as the basal component of a multiple daily injection (MDI) regimen. The basal insulin dose typically accounts for 40–60% of the total daily insulin requirement, with the remainder divided among pre-meal bolus injections of a rapid-acting insulin. Liprolog Basal is usually injected once daily (typically at bedtime or in the morning) or twice daily (morning and bedtime) depending on the individual’s glucose patterns and physician recommendation. The dose is adjusted based on self-monitoring of blood glucose (SMBG) or continuous glucose monitoring (CGM) data, targeting specific fasting and pre-meal blood glucose levels as agreed with the healthcare team.
In adults with type 2 diabetes, Liprolog Basal may be initiated when oral antidiabetic medications and lifestyle modifications no longer achieve adequate glycemic control. The recommended starting dose is typically 10 IU or 0.1–0.2 IU/kg once daily, usually at bedtime. The dose is then titrated upward in increments of 1–2 IU every 2–3 days until the fasting blood glucose target is consistently achieved. Common fasting glucose targets are 4.4–7.2 mmol/L (80–130 mg/dL), though individual targets may vary based on patient age, comorbidities, and hypoglycemia risk. If fasting glucose targets are met but daytime or postprandial glucose remains elevated, the addition of rapid-acting mealtime insulin or GLP-1 receptor agonist therapy should be considered.
Children
Insulin dosing in children with type 1 diabetes follows the same general principles as in adults, but requires particularly close supervision by a pediatric endocrinologist or diabetes specialist. Prepubertal children typically require 0.5–0.7 IU/kg/day of total insulin, while during puberty, requirements may increase to 1.0–1.5 IU/kg/day or higher due to growth hormone-mediated insulin resistance. Approximately 40–50% of the total daily dose is usually allocated to basal insulin. Children’s insulin needs can fluctuate significantly with growth, activity, illness, and dietary habits, necessitating regular review and adjustment.
Elderly
Elderly patients (≥65 years) are at increased risk of hypoglycemia due to several factors, including decreased renal function, impaired counter-regulatory hormone responses, irregular eating patterns, and polypharmacy. International guidelines, including those from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), recommend less stringent glycemic targets for older adults, particularly those with significant comorbidities, limited life expectancy, or cognitive impairment. A fasting blood glucose target of 5.0–8.3 mmol/L (90–150 mg/dL) and an HbA1c target of less than 8.0% may be appropriate for many older patients. Initial insulin doses should be conservative, with gradual titration and frequent monitoring.
Missed Dose
If you forget to take your dose of Liprolog Basal, take it as soon as you remember, unless it is close to the time for your next scheduled dose. In that case, skip the missed dose and resume your normal dosing schedule. Do not take a double dose to compensate for a missed injection, as this significantly increases the risk of severe hypoglycemia. If you are unsure about what to do after missing a dose, check your blood glucose level and contact your healthcare provider or diabetes educator for guidance. Keeping a consistent injection schedule and using reminders (such as phone alarms) can help prevent missed doses.
Overdose
An overdose of insulin causes hypoglycemia, which can range from mild (treated with oral glucose) to severe (requiring emergency medical intervention with intravenous glucose or glucagon injection). Symptoms of severe hypoglycemia include confusion, seizures, unconsciousness, and in rare cases, death. If you suspect an insulin overdose, immediately consume fast-acting carbohydrates (glucose tablets, fruit juice, sugar), check your blood glucose, and seek medical attention. Patients at risk should have a glucagon emergency kit available and ensure that family members and caregivers are trained in its use.
There is no specific defined toxic dose of insulin, as the severity of hypoglycemia depends on the amount of excess insulin relative to the patient’s food intake, physical activity, and baseline insulin sensitivity. Mild hypoglycemia (blood glucose 3.0–3.9 mmol/L or 54–70 mg/dL) can typically be self-treated by consuming 15–20 grams of fast-acting carbohydrate, rechecking blood glucose after 15 minutes, and repeating treatment if necessary. Severe hypoglycemia (blood glucose below 3.0 mmol/L or 54 mg/dL, or any episode requiring third-party assistance) is a medical emergency. Unconscious patients should not be given oral carbohydrates due to aspiration risk; instead, glucagon should be administered intramuscularly or subcutaneously by a trained caregiver, and emergency medical services should be contacted immediately.
What Are the Side Effects of Liprolog Basal?
Like all insulin preparations, Liprolog Basal can cause side effects, although not everybody experiences them. The most frequently reported adverse effect across all insulin therapies is hypoglycemia, which occurs when the blood glucose level drops below the normal range. The risk and severity of hypoglycemia depend on the insulin dose relative to carbohydrate intake and physical activity, the patient’s individual sensitivity to insulin, and various other factors discussed in the warnings section above.
The following side effects have been reported with Liprolog Basal and other insulin lispro preparations, categorized by frequency according to the standard MedDRA (Medical Dictionary for Regulatory Activities) convention:
Very Common
- Hypoglycemia (low blood sugar) — symptoms include sweating, trembling, hunger, rapid heartbeat, dizziness, confusion, blurred vision, difficulty concentrating, and in severe cases, loss of consciousness or seizures
Common
- Injection site reactions — redness (erythema), swelling, itching (pruritus), or pain at the injection site
- Local allergic reactions — mild skin reactions around the injection area
Uncommon
- Lipodystrophy — lipoatrophy (loss of fat tissue) or lipohypertrophy (accumulation of fat tissue) at injection sites, often due to failure to rotate injection sites adequately
- Peripheral edema — mild fluid retention, particularly when initiating or intensifying insulin therapy
Rare
- Systemic allergic reactions — generalized urticaria (hives), angioedema (swelling of face, lips, tongue, or throat), bronchospasm, hypotension, or anaphylaxis
- Insulin antibody formation — development of antibodies against insulin lispro, which in rare cases may necessitate dose adjustments
- Visual disturbances — temporary changes in vision due to rapid improvements in blood glucose control (refractive changes); these typically resolve within a few weeks
Lipodystrophy deserves particular attention because it is preventable. It occurs at sites of repeated insulin injections when patients fail to rotate their injection sites adequately. Lipohypertrophy (localized enlargement of fat tissue) is the more common form and appears as a soft, painless lump under the skin. Injecting into lipohypertrophic tissue can lead to erratic and unpredictable insulin absorption, contributing to unstable blood glucose levels. Lipoatrophy (localized loss of fat tissue) is less common with modern insulin analogues but can still occur. To prevent lipodystrophy, patients should systematically rotate their injection sites within a given anatomical region (e.g., different areas of the abdomen or thigh) and avoid injecting repeatedly into the same spot.
Peripheral edema (mild swelling, typically of the ankles and feet) may occur when insulin therapy is initiated or significantly intensified, particularly in patients with previously poor glycemic control. This is usually transient and resolves spontaneously as blood glucose levels stabilize. It is thought to be related to the sodium-retaining effect of insulin on the renal tubules. If edema persists or is significant, the patient should consult their healthcare provider to rule out other causes.
Systemic allergic reactions to insulin are rare with modern recombinant insulin analogues but can occur. True insulin allergy should be distinguished from localized injection site reactions, which are far more common and usually mild. If a patient experiences symptoms suggestive of a systemic allergic reaction (widespread rash, difficulty breathing, rapid heartbeat, drop in blood pressure), they should seek immediate medical attention. Desensitization protocols are available for patients with confirmed insulin allergy who have no suitable alternative treatment.
Contact your healthcare provider if you experience: frequent or severe hypoglycemia episodes; persistent or worsening injection site reactions; unexplained changes in your blood glucose patterns; signs of an allergic reaction (rash, itching, swelling, difficulty breathing); or any new or unusual symptoms that concern you. Never stop taking insulin without medical advice, as this can lead to dangerous hyperglycemia and diabetic ketoacidosis (in type 1 diabetes).
How Should You Store Liprolog Basal?
Proper storage of insulin is essential to ensure its effectiveness and safety. Insulin that has been exposed to extreme temperatures, frozen, or stored beyond its recommended use period may lose potency, leading to inadequate blood glucose control and potentially dangerous hyperglycemia. Liprolog Basal, like all insulin suspensions, is sensitive to both heat and cold and must be handled with care.
Before first use (unopened cartridges): Store in a refrigerator at 2–8°C (36–46°F). Keep the cartridge in the outer carton to protect from light. Do not store in or near the freezer compartment, and do not freeze. If Liprolog Basal has been accidentally frozen, do not use it — discard it safely. Frozen insulin may appear normal after thawing but its biological activity may be reduced or altered due to protein denaturation and crystalline structure disruption.
After first use (cartridge in use): The cartridge in use may be stored at room temperature (not above 30°C / 86°F) for up to 28 days. It should not be refrigerated while in use, as cold insulin injections can be more uncomfortable and may alter absorption kinetics. Keep the cartridge away from direct heat sources (radiators, direct sunlight, car dashboards) and protect from light. After 28 days, discard the cartridge even if insulin remains, because the preservative system (metacresol and phenol) becomes less effective over time, and bacterial contamination cannot be excluded.
Before each injection: Gently roll the cartridge between your palms 10 times and invert it 180 degrees 10 times to resuspend the crystalline insulin evenly. Do not shake vigorously, as this can cause frothing, which may affect dose accuracy. After mixing, the suspension should appear uniformly white and cloudy. If the resuspended material is clumpy, contains particles, or appears frosted (indicative of freezing damage), do not use the cartridge.
Keep Liprolog Basal out of the reach and sight of children. Do not use after the expiry date printed on the label and carton. When traveling, carry insulin in a cool bag or insulated pouch to protect it from temperature extremes, but ensure it does not come into direct contact with ice packs, as freezing will damage the product. Used needles and cartridges should be disposed of in an approved sharps container according to local regulations.
What Does Liprolog Basal Contain?
Understanding the composition of your medication is important, particularly for patients with known allergies or sensitivities to specific pharmaceutical ingredients. Liprolog Basal is formulated as a sterile suspension for subcutaneous injection, supplied in 3 mL glass cartridges (300 IU per cartridge) at a concentration of 100 IU/mL.
Active ingredient: Insulin lispro protamine — 100 IU/mL (equivalent to 3.5 mg/mL). Insulin lispro protamine is produced by recombinant DNA technology using Escherichia coli and then complexed with protamine sulfate to form a crystalline suspension with intermediate-acting pharmacokinetic properties.
Excipients (inactive ingredients):
- Protamine sulfate: A basic protein derived from fish sperm that binds to insulin lispro, forming crystals that slow subcutaneous absorption and extend the duration of action. Patients with fish allergy should discuss this with their doctor, although cross-reactivity is very rare.
- Metacresol (m-cresol): An antimicrobial preservative that prevents bacterial contamination of the multi-dose cartridge during the 28-day in-use period.
- Phenol: An additional antimicrobial preservative used alongside metacresol for dual-preservative protection.
- Glycerol: An isotonicity agent that adjusts the osmotic pressure of the formulation to match physiological conditions, ensuring comfortable injection.
- Dibasic sodium phosphate (7H2O): A buffering agent that maintains the pH of the formulation within the optimal range for insulin stability.
- Zinc oxide: Contributes to the stability of the insulin crystal structure and assists in the controlled release of insulin from the injection depot.
- Hydrochloric acid and/or sodium hydroxide: Used for pH adjustment during manufacture.
- Water for injections: The vehicle/solvent.
Liprolog Basal does not contain latex in its cartridge or closure system. The cartridge is made of Type I glass with aluminum ferrules and rubber closures (bromobutyl). Patients with known latex allergy can generally use Liprolog Basal cartridges without concern, but should always verify with the specific product labeling and manufacturer information for their market.
Frequently Asked Questions About Liprolog Basal
Both Liprolog Basal and NPH (Neutral Protamine Hagedorn) insulin are intermediate-acting insulins that use protamine complexation to delay absorption. The key difference is the base insulin: Liprolog Basal uses insulin lispro (a rapid-acting analogue), while NPH uses regular human insulin. In practice, their pharmacokinetic profiles are broadly similar, with onset at 1–2 hours, peak at 4–12 hours, and duration of 15–24 hours. Liprolog Basal is commonly used alongside rapid-acting Liprolog (insulin lispro) as part of a matched analogue basal-bolus regimen. Your doctor will determine which intermediate-acting insulin is most appropriate for you.
Switching between different basal insulin types should only be done under medical supervision. Long-acting insulin analogues (such as insulin glargine or insulin degludec) have a flatter pharmacokinetic profile with less peak effect and longer duration compared with intermediate-acting insulins like Liprolog Basal. When switching, your doctor will adjust the dose and timing of administration. Typically, the total daily dose of basal insulin may need to be reduced by approximately 20% when switching from twice-daily intermediate-acting insulin to once-daily long-acting insulin, with subsequent titration based on blood glucose monitoring.
Liprolog Basal is a suspension, meaning the insulin crystals settle to the bottom of the cartridge during storage. If injected without proper resuspension, the dose delivered may contain more or less insulin than intended, leading to unpredictable blood glucose levels. Gently rolling the cartridge between your palms 10 times and inverting it 10 times ensures the crystals are evenly distributed throughout the liquid, so each injection delivers a consistent and accurate dose. Never shake the cartridge vigorously, as this creates air bubbles that can affect dose accuracy.
If you accidentally inject more Liprolog Basal than prescribed, your blood sugar may drop too low (hypoglycemia). Immediately eat or drink something containing fast-acting carbohydrates, such as glucose tablets, fruit juice, or a sugary drink. Check your blood glucose levels frequently over the next several hours, as the intermediate-acting profile means the effect will persist for many hours. If you experience severe symptoms (confusion, unconsciousness, seizures), someone should administer glucagon if available and call emergency services. Always inform your doctor about any insulin overdose episodes.
Yes, you can travel with Liprolog Basal, but proper precautions are important. Carry your insulin in your hand luggage (not in checked baggage, which may freeze in the aircraft cargo hold). Use an insulated case to protect from temperature extremes but avoid direct contact with ice packs. Carry a letter from your doctor explaining your need for insulin and injection supplies, especially for air travel. If crossing time zones, discuss with your doctor how to adjust your injection schedule. Always carry extra supplies (cartridges, pen needles, glucose tablets, blood glucose monitor) in case of unexpected delays.
Liprolog Basal and Humalog Basal are essentially the same product — both contain insulin lispro protamine at 100 IU/mL, manufactured by Eli Lilly. The brand name used depends on the market: “Humalog” is the more widely known brand name in many countries, while “Liprolog” is the brand name used in certain European and other markets. They have the same active ingredient, concentration, formulation, and clinical properties. If you are switching between brand names, no dose adjustment is typically necessary, but always confirm with your pharmacist or doctor.
References
- European Medicines Agency (EMA). Liprolog Basal – Summary of Product Characteristics. EMA/CHMP, last updated 2024. Available at: www.ema.europa.eu
- American Diabetes Association (ADA). Standards of Care in Diabetes – 2025. Diabetes Care. 2025;48(Suppl. 1). doi: 10.2337/dc25-SINT
- Davies MJ, Aroda VR, Collins BS, et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the ADA and EASD. Diabetes Care. 2022;45(11):2753–2786. doi: 10.2337/dci22-0034
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List, 2023. Geneva: WHO; 2023.
- National Institute for Health and Care Excellence (NICE). Type 1 Diabetes in Adults: Diagnosis and Management (NG17). Last updated 2022. Available at: www.nice.org.uk
- International Diabetes Federation (IDF). IDF Diabetes Atlas, 10th Edition, 2021. Available at: diabetesatlas.org
- Eli Lilly and Company. Liprolog Basal (insulin lispro protamine suspension) – Prescribing Information. 2024.
- Hirsch IB. Insulin Analogues. N Engl J Med. 2005;352:174–183. doi: 10.1056/NEJMra040832
- DeWitt DE, Hirsch IB. Outpatient Insulin Therapy in Type 1 and Type 2 Diabetes Mellitus: Scientific Review. JAMA. 2003;289(17):2254–2264. doi: 10.1001/jama.289.17.2254
- British National Formulary (BNF). Insulin lispro – Monograph. Available at: bnf.nice.org.uk
Medical Editorial Team
Medical Content
Written by iMedic Medical Editorial Team – Specialists in Endocrinology and Clinical Pharmacology
Medical Review
Reviewed by iMedic Medical Review Board according to ADA, EASD, EMA, and WHO guidelines
Evidence Standard
Level 1A – Based on systematic reviews, meta-analyses of RCTs, and international clinical guidelines
Independence
No pharmaceutical company funding or advertising. Fully independent medical editorial content
All medical content on iMedic is reviewed by qualified healthcare professionals. Our editorial process follows the GRADE evidence framework and adheres to international medical guidelines. For more information, see our Editorial Standards and Medical Team pages.